ST. LOUIS -- Daniel F. Hoft, M.D., Ph.D., has been named director of the division of infectious diseases, allergy and immunology in the department of internal medicine. The new division merges the division of immunobiology, which Hoft previously had directed, with the division of infectious diseases.
|Daniel Hoft, M.D.|
Hoft, who joined Saint Louis University School of Medicine as an assistant professor of internal medicine in 1992, is a renowned researcher in the areas of immunology, infectious diseases and vaccine development. He is an internationally recognized tuberculosis vaccine expert. In addition, his research has led to the development of new vaccines in pre-clinical development for Chagas disease, a major cause of cardiac and gastrointestinal problems throughout Latin America.
"Given the rising problem of tuberculosis across the world, particularly among immune-compromised hosts and in association with TB drug-resistance, the need for a safe and effective vaccine has become even more critical," said Adrian Di Bisceglie, M.D., chairman and professor of internal medicine and holder of the Bander Chair in Internal Medicine.
"Dr. Hoft and his investigators at Saint Louis University have been among the leaders in the efforts to develop such a vaccine."
Hoft is a graduate of the University of Missouri-Columbia's School of Medicine. He received his Ph.D., from the University of Iowa, where he also was a resident and a fellow in infectious diseases.
Hoft has played a leadership role in the School of Medicine's M.D./Ph.D. program, mentoring a large number of Ph.D. students and post-doctoral trainees. The author of more than 50 peer-reviewed journal articles, Hoft has served as principle investigator for eight NIH grants, co-investigator for more than six other NIH grants, and principle investigator of 12 TB vaccine clinical trials. He also has participated in numerous National Institutes of Health review committees for research grants and as an advisor to the World Health Organization and other international bodies.
"I look forward to Dr. Hoft's efforts to build upon the strong tradition of excellence in the division of infectious diseases and the Center for Vaccine Development at Saint Louis University," Di Bisceglie said. "I have every confidence that Dr. Hoft will be an outstanding leader for our students, residents and faculty members in that division and beyond."
Established in 1836, the School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: infectious disease, liver disease, aging and brain disease, cancer and heart/lung disease. The school's department of internal medicine celebrates its centennial in 2011.